 Clinical data from dual combination COM701nivolumab MSS-CRC cohort expansion study Research data on differentiation of PVRIG from other immune checkpoints HOLON, Israel , Oct. 6, 2022 PRNewswire -- Compugen Ltd. Nasdaq: CGEN, a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that it will present new clinical data from its dual combination COM701nivolumab MSS-CRC cohort expansion study and research data on the differentiation of PVRIG from other immune checkpoints in two oral presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer SITC, taking place between 10-12 November 2022, Boston, MA. 